Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion

2018 ◽  
Vol 95 (12) ◽  
pp. 1149-1154 ◽  
Author(s):  
Abdullah Ozkaya ◽  
Hatice Nur Tarakcioglu ◽  
Ipek Tanir
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Dexamethasone Implant ◽  
Vein Occlusion

Does Intravitreal Dexamethasone Implant Fragmentation Affect Clinical Outcomes in Macular Edema from Branch Retinal Vein Occlusion

2016 ◽  
Vol 236 (2) ◽  
pp. 74-80 ◽  
Author(s):  
Jong Chan Im ◽  
Jae Pil Shin ◽  
In Taek Kim ◽  
Dong Ho Park
Keyword(s):  
Macular Edema ◽  
Clinical Outcomes ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Dexamethasone Implant ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone Implant ◽  
Central Subfield Thickness ◽  
Intravitreal Dexamethasone ◽  
Rate Frequency

Purpose: The aim of this study was to evaluate the effect of intravitreal dexamethasone implant fragmentation on clinical outcomes in branch retinal vein occlusion (BRVO)-induced macular edema (ME). Methods: All consecutive patients receiving an intravitreal dexamethasone implant for BRVO-induced ME were divided into two groups depending on whether the implant was intact or had fragmented into two or more pieces on postoperative day 1. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), and central subfield thickness (CST) on spectral-domain optical coherence tomography were measured for 6 months. Results: Among 68 patients, the implant was fragmented in 6 (8.8%) and intact in 62 (91.2%) eyes. The two groups did not differ in BCVA and CST at any time point (all p > 0.05). There was no difference in the ME recurrence rate, frequency of IOP elevation, and cataract progression between the two groups (all p > 0.05). Conclusion: Fragmentation seemed not to influence clinical outcomes of intravitreal dexamethasone implantation during 6 months or to alter the frequency of adverse events.

Sign in / Sign up

Export Citation Format

Share Document